| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
CORRESPONDENCE |
RESPONSE: Re: Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia
Affiliation of authors: Department of Pathology, Royal University Hospital and College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Correspondence to: Anurag Saxena, MD, Department of Laboratory Medicine, Royal University Hospital, Saskatoon SK, Canada (e-mail: saxena@sask.usask.ca).
| The first 10% of the full text of this article appears below. |
The Correspondences by Freeman et al., Vargas et al., Iglesias-Serret et al., Nenning et al., and Dicker et al. address four key points regarding MCL-1 promoter nucleotide insertions.
Mutations or polymorphisms?
Because our control group was too small (n = 18) to determine population prevalence, we simply referred to these promoter changes as nucleotide insertions. Based on an analysis of 55 additional control samples, we have now found that the allele frequencies in the Saskatchewan population are 0.98 for the wild-type allele and 0.01 each for 6- and 18-nucleotide insertion alleles (Fig. 1A and B). The presence of these nucleotide insertions in other healthy populations is also reported
Location. Effect on gene expression. Prognostic significance.
Related Correspondence
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2005 97: 1088-1089.
J Natl Cancer Inst 2005 97: 1089-1090.
J Natl Cancer Inst 2005 97: 1090-1091.
J Natl Cancer Inst 2005 97: 1091-1092.
J Natl Cancer Inst 2005 97: 1092-1093.